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ABSTRACT 
CHANGES IN NEUROMUSCULAR PERFORMANCE THROUGOUT THE 
MENSTRUAL CYCLE IN PHYSICALLY ACTIVE FEMALES   
JOSEPH D. ALBERT  
2016 
Context: In the United States, an excess of $1 billion is spent annually on anterior 
cruciate ligament (ACL) repair surgeries/rehabilitation programs in varsity female sports. 
Research has indicated that female athletes may be 2 to 10 times more likely to sustain an 
ACL tear than their male counterparts. Objective: The purpose of this study was to 
analyze the neuromuscular changes in females during different phases of the menstrual 
cycle. Design: Observational Cohort Setting: Laboratory Participants: Fifty (50) 
physically active college aged females (25 on oral contraception) were recruited to 
participate in three separate visits throughout one menstrual cycle. The groups were 
similar at baseline. Intervention: Visits coincided with follicular, ovulatory, and the 
luteal phase of the cycle.  At each visit, participants had their blood drawn to assess for 
estradiol, progesterone, and relaxin levels.  Along with blood measurements, isokinetic 
quadriceps strength at 60°/sec, 180°/sec, and 300°/sec, and knee joint laxity were 
measured at each visit. Main Outcome Measures:  Isokinetic quadriceps strength, KT-
1000 measurements, blood assays. Results:  Isokinetic peak torque at 60°/sec was 
significantly lower during the follicular (151.6 ± 26.8 NM) than during the ovulatory 
phases (157.5 ± 27.1 NM, p<0.05).  Isokinetic peak torque at 180°/sec was significantly 
lower during the follicular phase (98.7 ± 17.9 NM) than the ovulatory (107.1 ± 19.5 NM, 
p<0.05) and luteal phases (111.2 ± 19.5 NM, p<0.05).  Results were similar for the 
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300°/sec isokinetic testing with significantly lower peak torque during follicular (79.0 ± 
16.0 NM) than the ovulatory (85.4 ± 16.8 NM, p<0.05) or luteal phases (85.7 ± 16.0 NM, 
p<0.05).  No differences were observed for knee joint laxity among any of the visits. 
Conclusion: Results show that muscle strength is lowest during the follicular phase of 
the menstrual cycle and muscle strength and knee joint laxity are independent of hormone 
level fluctuations.  
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CHAPTER 1  
Introduction 
 Female athletes are at greater risk of anterior cruciate ligament (ACL) injuries than 
males at the same competitive level.1 It has been indicated that adolescent females may 
be 2 to 10 times more likely to sustain an ACL tear than their male counterparts.2,3 In the 
United States, an excess of $1 billion is spent annually on over 125,000 ACL repair 
surgeries and rehabilitation programs in varsity female sports.3  
 A possible mechanism for the increased rate of serious knee injuries in female 
athletes could be related to neuromuscular differences.4,5 Some research suggests that this 
difference in injury rate could be related to differences in neuromuscular training between 
males and females.5,6 Other studies have reported that factors such as female sex 
hormones may also play a role.7 6,8-11 Since females go through a monthly menstrual 
cycle and are known to have an increased risk for ACL injury, it should be determined if 
hormonal fluctuations have an impact on neuromuscular factors.  
 Estrogen, progesterone, and relaxin are some female sex hormones that fluctuate 
throughout the normal menstrual cycle.12 Hormonal fluctuations throughout the menstrual 
cycle have been reported to have adverse effects on athletic performance and some of 
these effects may place them at a greater risk of injury.12 The fluctuations in female sex 
hormones concentrations throughout the menstrual cycle combined with the possible 
relationship of hormone levels to neuromuscular risk factors, indicate the possibility that 
injury rates may vary based on hormonal changes throughout the menstrual cycle.  
 While controversial in the effect they have on knee injury rates, female sex 
hormones have been reported to change the tensile properties of ligaments and tendons. 
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Some research has reported an increase in knee joint laxity during certain phases of the 
menstrual cycle.13-16 These reports indicate that hormone changes could lead to an 
increase in joint laxity, thereby potentially increasing the risk of ACL injury in females. 
In contrast, there are other reports indicating that knee joint laxity is not affected by 
hormonal changes during the menstrual cycle.17-20   
  Female sex hormones have been reported to cause changes in quadriceps strength 
and variations in muscle relaxation rates throughout the menstrual cycle.7,15 Athletes with 
increased quadriceps muscle strength combined with decreased hamstring strength have 
been linked to an increased risk of ACL injuries.21 It has been reported that females have 
an increased risk of non-contact knee injuries because they have lower hamstring-to-
quadriceps strength ratios than males.6 In studies using isokinetic testing, females have 
been reported to have more than twice the muscle strength in their quadriceps compared 
to their hamstrings.6 Having quadriceps strength that is more than double of that of the 
hamstrings has been reported to assist in anterior tibial forces at the knee and therefore 
may be linked to an increase in the occurrence of ACL injuries.22  
Since the problem with ACL injuries is so significant, special attention should be 
paid to the extrinsic risk factors associated with the mechanisms of ACL injury. The 
primary purpose of this study is to analyze the neuromuscular changes in females during 
different phases of the menstrual cycle. The secondary aims of this study are to analyze: 
1. The muscle strength of the quadriceps in females throughout the three phases 
of the menstrual cycle, 
2. The knee joint laxity in females throughout the three phases of the menstrual 
cycle, and 
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3. Hormonal changes in estrogen, progesterone, and relaxin, throughout the 
menstrual cycle, in the oral contraceptive group and non-contraceptive group. 
Delimitations/Limitations 
 The delimitations of this study are the strong methodology, the blinding of 
researcher completing KT 1000 testing, and use of an only female population. The 
limitations are no monitoring of oral contraceptive use and the potential for participant 
drop out.  
Definition of terms 
Anterior Cruciate Ligament (ACL): Comprises three twisted bands. This ligament 
prevents the femur from moving posteriorly during weight bearing and limits 
anterior translation of the tibia in non-weight bearing.23   
Isokinetic: Movement that occurs at a constant velocity. 24  
Monophasic oral contraceptive: A birth control pill that contains the same amount 
of estrogen and progesterone in each pill. 25  
Estrogen: The primary female sex hormone that is secreted primarily by luteal 
cells. 12,23  
Progesterone: The main regulator of the menstrual cycle, it helps prepare the 
female body for conception and inhibits the production of luteinizing hormone. 
12,23  
Follicle Stimulating Hormone (FSH): A hormone released during the menstrual 
cycle that stimulates the maturation of an ovarian follicle. 12,23  
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Luteinizing Hormone (LH): A hormone released at the mid-cycle of menstruation 
that stimulates the development of luteum and the endocrine structure that 
secretes progesterone and estrogens. 12,23  
Relaxin: A hormone that is believed to be responsible for connective tissue 
changes during late-pregnancy that helps to accommodate childbirth. 26 
Assumptions 
 This study assumes that the participants are either in the contraceptive group or 
non-contraceptive group will continue with the protocol in order to stay in that particular 
group.    
Hypothesis 
 Hypothesis 1: We hypothesize that the quadriceps strength will decrease as estrogen 
increases during the menstrual cycle.  
 Hypothesis 2: Our hypothesis is that knee joint laxity will increase during the 
follicular phase of the menstrual cycle.  
 Hypothesis 3: Our hypothesis is that participants in the non-oral contraceptive group 
will show changes in quadriceps strength and joint laxity compared to the oral 
contraceptive group.  
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CHAPTER 2  
Review of Literature 
 In order to fully understand the effects that hormones have on ACL joint laxity, it 
is important to gain an understanding of knee anatomy, mechanism of injury, female sex 
hormones and assessment strategies. This review of literature will address the following 
topics:  1) Anatomy, 2) Etiology, 3) Epidemiology, 4) Knee Laxity Assessment, 5) 
Isokinetic Muscle Training, 6) Female Menstrual Cycle Hormones. 
Anatomy  
 The knee joint complex is formed by the tibiofemoral, tibiofibular, and 
patellofibular joints. It has little bony support which means it has to rely on more soft 
tissues to transmit force through the joint.27  The bony anatomy involves 4 major bones: 
the femur, tibia, fibula and patella.23 The femur is the longest and strongest bone in the 
body and accounts for approximately a quarter of the body’s height.27 The medial and 
lateral condyles are located on the inferior portion of the femur.27 The condyles are 
convex structures that are covered in articular hyaline cartilage in order to freely 
articulate with the menisci of the tibia.27  The articular surfaces of the condyles are 
separated by the deep intercondylar notch of the femur on the posterior side while 
remaining adjoined on the anterior side.27 On the anterior side, the two condyles form the 
femoral trochlea which allows articulation with the patella.23 The proximal end of the 
tibia contains the tibial plateau, which is slightly concave shaped and articulates with the 
femoral condyles.23 
The patella is the largest sesamoid bone in the body and is located in the patellar 
tendon and glides over the femoral trochlea.27 The patella serves a mechanical and 
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protective purpose by the way it dissipates forces from the extensor muscles and protects 
the anterior side of the knee.27 
 The knee is classified as a double condyloid articulation that is capable of three 
degrees of freedom: (1) flexion and extension, (2) internal and external rotation, (3) 
abduction and adduction.27  
The menisci serve to make up the anatomical differences between the articular 
surfaces of the tibia and femur.27 There are two oval shaped fibrocartilage rings or 
menisci, which deepen the facets of the tibia, cushion stress placed on the knee joint and 
also maintain spacing between the tibial plateau and femoral condyles.23 The two menisci 
are named based on their anatomical location. The medial meniscus is on the medial 
portion of the tibial plateau and is “C” shaped.23 It is wider on the posterior side than the 
anterior side and offers more knee stabilization than the lateral meniscus.23 The lateral 
meniscus is both smaller and more mobile than the medial meniscus and is “O” shaped. 
23,27 It attaches to several different muscles and ligaments which distort its shape to aid in 
stabilizing the knee while moving through the entire range of motion.27  There are three 
main portions of the menisci. The outer portion is known as the “red zone” and has the 
most vascularization, which means it is most likely to heal if torn.27  The middle portion 
is known as the “pink zone” and is less vascularized than the “red zone”.27  The “white 
zone” is the most inner portion of the menisci and is avascular which means it has no 
direct vascularization.27   
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Figure 1: Medical Anatomy and Illustrations 
 
Medical Anatomy and Illustrations. Google Images. 
https://www.google.com/search?q=anatomy+of+the+knee&es_sm=93&source=lnms&tb
m=isch&sa=X&ved=0CAcQ_AUoAWoVChMIgpX5gOi1yAIVAnc-
Ch1k1gKu&biw=1517&bih=714&dpr=0.9#tbm=isch&q=anatomy+of+the+knee+menisc
us+vascularity&imgrc=VN44MWdxfhF0jM%3A. Accessed October 9, 2015. 
Ligaments 
The knee is held together almost entirely by four ligaments: the medial collateral 
ligament (MCL), the lateral collateral ligament (LCL), the anterior cruciate ligament 
(ACL), and the posterior cruciate ligament (PCL).23 The MCL is the primary medial 
stabilizer of the knee and contains both a deep and superficial layer.27 The anterior fibers 
of the MCL are taut in the midrange of knee flexion and both the anterior and posterior 
fibers are taut in complete extension.27 The LCL is the primary lateral stabilizer of the 
knee and also limits external and internal tibial rotation.27 It is a fibrous, cord like 
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structure and helps the lateral knee to withstand increased stress from varus forces and 
also the initial contact phase of gait.23,27 The anterior cruciate ligament (ACL) protects 
against a number of different knee movements but it is most known for its protection of 
anterior translation of the tibia on the femur.27 Other movements that the ACL helps 
protect against are internal and external rotation of the tibia on the femur and also 
hyperextension of the tibiofemoral joint.23,27 There are two discrete segments of the ACL, 
the anteromedial bundle and the posterolateral bundle. When the knee is fully extended 
the posterolateral bundle is taut and when the knee is fully flexed the anteromedial bundle 
is taut.27 This allows for the ACL to provide support throughout a large range of 
motion.27 The PCL is another primary stabilizer of the knee and prevents internal rotation 
of the tibia, hyperextension of the knee, anterior translation of the femur during weight 
bearing, and posterior translation of the tibia in non-weight bearing.23 It has two main 
components: the anterolateral and posteromedial bundles. The anterolateral bundle is taut 
when the knee is flexed and the posteromedial bundle is taut when the knee is extended. 
Together, the ACL and PCL work with each other in what is known as the “screw home 
mechanism”.27 In this mechanism, the two ligaments encircle each other in flexion and 
unwind in extension.27  
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Figure 2: Normal Anatomy  
 
Normal Anatomy. Google Images. 
https://www.google.com/search?q=anatomy+of+the+knee&es_sm=93&source=lnms&tb
m=isch&sa=X&ved=0CAcQ_AUoAWoVChMIgpX5gOi1yAIVAnc-
Ch1k1gKu&biw=1517&bih=714&dpr=0.9#tbm=isch&q=anatomy+of+the+knee+ligame
nts&imgrc=QukVOpzplapfkM%3A. Accessed October 9, 2015. 
Muscles 
There are many muscles that play a role in the static and dynamic stabilization of 
the knee joint. They are located on both the anterior and posterior aspect of the thigh and 
leg and assist with flexion, extension, and internal and external tibial rotation.23,27  
The main muscles that assist the knee with flexion are the following: biceps 
femoris, semitendinosus, semimembranosus, gracilis, sartorius, gastrocnemius, and 
popliteus muscles.23 The origin of the biceps femoris is quite complex. The long head 
originates at the ischial tuberosity and sarcotuberous ligament while the short head 
originates at the lateral lip of the linea aspera and upper two-thirds of the supracondylar 
line.27 The insertion of the biceps femoris is to the lateral fibular head and the lateral 
tibial condyle.27 The semitendinosus originates at the ischial tuberosity and inserts at the 
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medial portion of the tibial flare.27 The semimembranosus originates at the ischial 
tuberosity and inserts at the posteromedial portion of the tibia’s medial condyle.27 The 
origin of the gracilis is the symphysis pubis and the inferior ramus of the pubic bone 
while the insertion at the proximal portion of the antero-medial tibial flare.27 The 
sartorius muscle originates at the anterior superior illaic spine and also inserts at the 
proximal portion of the antero-medial tibial flare.27 The gastrocnemius is another muscle 
that has a complex origination. The medial head originates at the posterior surface of the 
medial femoral condyle and the adjacent portion of the femur and knee capsule. The 
lateral head originates at the posterior surface of the lateral femoral condyle and the 
adjacent portion of the femur and knee capsule. The gastrocnemius inserts to the 
calcaneus via the Achilles tendon.27 The origination of the popliteus muscle is the lateral 
femoral condyle and the oblique popliteal ligament. The insertion of the popliteus is to 
the posterior tibia superior to the soleal line and to the fascia covering the soleus 
muscle.27 
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Figure 3: Knee Anatomy 
 
Knee Anatomy. Google Images. 
https://www.google.com/search?q=anatomy+of+the+knee&es_sm=93&source=lnms&tb
m=isch&sa=X&ved=0CAcQ_AUoAWoVChMIgpX5gOi1yAIVAnc-
Ch1k1gKu&biw=1517&bih=714&dpr=0.9#tbm=isch&tbs=rimg%3ACVUasO08WR4FIj
iuWJ21hFmyPf8ibQDBfw_1RLH9gH_1kK2J7m2L9E673Z2dXCwCkI1q0oPqRyCvdtw
f93tFRFr-
aiCSoSCa5YnbWEWbI9Ee7OYkBw7cniKhIJ_1yJtAMF_1D9ERKwE6T3sXpWYqEgks
f2Af-QrYnhGVC5-
NUc1q2SoSCebYv0TrvdnZEYEZ1jltgsUVKhIJ1cLAKQjWrSgR0ahd-MTuKKQqEgk-
pHIK923B_1xFJD_1CpOEF1mSoSCXe0VEWv5qIJESNkEOLVC9Rb&q=anatomy%20
of%20the%20knee%20muscles&imgrc=-hpxpAw9xF1C3M%3A. Accessed October 9, 
2015. 
The semitendinosus, semimembranosus, gracilis, sartorius, and popliteus muscles 
all assist in both knee flexion and internal tibial rotation. The biceps femoris is 
responsible for both knee flexion and external rotation of the tibia.23  
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  Knee extension is accomplished with the help of the following muscles: the 
vastus lateralis, vastus medialis, vastus intermedius and rectus femoris, all of which 
combine to form the quadriceps femoris muscle group.27 The vastus lateralis’ origination 
is quite complex. It originates at the proximal interochanteric line, greater trochanter of 
the femur, gluteal tuberosity and the upper one half of the linea aspera. The insertion of 
the vastus lateralis is to the patellar tendon which attaches to the tibial tubercle.27 The 
origination of the vastus medialis is split into two main portions. The longus portion 
originates at the distal half of the intertrochanteric line and the medial portion of the linea 
aspera. The oblique portion originates from tendons attached to the adductor longus and 
adductor magnus.27 The insertion of the vastus medialis is the patellar tendon which 
attaches at the tibial tubercle.27 Another muscle that is part of the quadriceps femoris 
muscle group is the vastus intermedius. It originates at the anterolateral portion of the 
upper two thirds of the femur and also from the lower one half of the linea aspera. Like 
the other quadriceps muscles it inserts at the tibial tubercle via the patella and patellar 
tendon.27 The rectus femoris is the last of the quadriceps femoris muscle group. It 
originates at the anterior inferior iliac spine and the groove located superior to the 
acetabulum. The insertion of this muscle is also the tibial tubercle via the patella and the 
patellar ligament.27  
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Figure 4: Fascia, Bones and Muscles 
 
Fascia, Bones, and Muscles – Being Human. Google Images. 
https://www.google.com/search?q=anatomy+of+the+knee&es_sm=93&source=lnms&tb
m=isch&sa=X&ved=0CAcQ_AUoAWoVChMIgpX5gOi1yAIVAnc-
Ch1k1gKu&biw=1517&bih=714&dpr=0.9#tbm=isch&tbs=rimg%3ACVUasO08WR4FIj
iuWJ21hFmyPf8ibQDBfw_1RLH9gH_1kK2J7m2L9E673Z2dXCwCkI1q0oPqRyCvdtw
f93tFRFr-
aiCSoSCa5YnbWEWbI9Ee7OYkBw7cniKhIJ_1yJtAMF_1D9ERKwE6T3sXpWYqEgks
f2Af-QrYnhGVC5-
NUc1q2SoSCebYv0TrvdnZEYEZ1jltgsUVKhIJ1cLAKQjWrSgR0ahd-MTuKKQqEgk-
pHIK923B_1xFJD_1CpOEF1mSoSCXe0VEWv5qIJESNkEOLVC9Rb&q=anatomy%20
of%20the%20knee%20muscles&imgrc=Afez-4vCuz-D8M%3A. Accessed October 9, 
2015. 
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Etiology 
 The primary purpose of the ACL is to prevent anterior translation of the tibia on 
the femur.27 It also helps with the “screw home mechanism” and limits hyperextension.23 
The most common mechanism of injury to the ACL occurs when the tibia is externally 
rotated and the knee is in a valgus position.23,24,27 This position puts the most strain on the 
ACL and often times when an extreme valgus force is applied the MCL and medial 
meniscus can also be injured.23,27 Other mechanisms of injury include forced 
hyperextension, non-contact hyperextension, and non-contact deceleration.27 Studies have 
shown that as many as 78% of ACL injuries occur from non-contact rotational 
mechanisms.24  
 There are also other anatomical structures that assist the ACL and prevent injuries 
to it. The hamstrings are known to help prevent both hyperextension of the knee and 
anterior tibial translation.24,28 Females have been reported to have decreased dynamic 
knee control compared to males.3 It has been found that muscle strength and coordination 
are known to have a large role in injury prevention.4 Internal rotation is another knee 
movement that benefits from muscle stabilizers, the biceps femoris, tensor facial latae 
and the iliotibial band combine to limit internal rotation.28 Relating to the meniscus, it is 
found that the medial meniscus offers more aid to the ACL than the lateral meniscus 
because it helps reduce anterior translation of the tibia on the femur.28 
 In regards to ACL injuries one must look at the many potential factors that could 
predispose an individual to ACL injuries. There are a number of different risk factors that 
are generally classified as intrinsic or extrinsic. Intrinsic risk factors are generally more 
difficult to control and involve individual physiological and psychological factors.23 
15 
 
Some intrinsic risk factors of the knee include joint laxity, limb alignment (Q-Angle), 
narrow intercondylar notch width, small ACL size, and genu recurvatum.27 Extrinsic risk 
factors are more manageable and are seen as something that could be part of an injury 
prevention plan.27 Some examples of extrinsic risk factors include muscle strength and 
endurance, muscle coordination and activation, playing style, playing environment, 
navicular drop, anterior pelvic tilt, and a wider pelvis to femoral length ratio.23,27  
The increased ACL injury rate in female athletes when compared to male athletes 
is explained through several theories. One suggested mechanism for the increase in 
injuries is the increased Q-angle (quadriceps angle) in females. Q-angle refers to the 
angle of a line from the anterior-superior-iliac-spine to the middle of the patella and from 
the middle of the patella to the tibial tubercle.27 Females typically have a greater Q-angle 
than males because of the anatomical differences in the hip to accommodate for child 
birth. While some clinicians and researchers readily accept this theory,29 other research 
has indicated that no relationship between Q-angle and ACL injuries exists.9   
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Figure 5: Diagnosis – Powell Orthopedics 
 
Diagnosis - Powell Orthopedics. Google Images. 
http://www.leadingmd.com/virtual/education/assets/q_angle.gif. Accessed November 16, 
2015. 
 Another anatomical difference between males and females is the size of the 
intercondylar notch in the femur. Females typically have a more narrow intercondylar 
notch than males relative to their body size.30 Some researchers believe that the narrow 
notch itself causes the increase in ACL injuries,29,31 while others believe that the narrow 
notch results in the ACL being more narrow thus decreasing the strength of the 
ligament.30 Research shows that a narrower intercondylar notch increases the likelihood 
of an ACL injury.29,30,31 However, research involving the intercondylar notch is 
inconclusive in determining the correlation between intercondylar notch width and ACL 
size.   
 Neuromuscular differences have been suggested as another possible mechanism 
for the increase in the rate of serious knee injuries in female athletes.4,5 After maturation, 
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it has been found that female athletes tend to land with greater medial motion of the 
knees and also a greater lower extremity valgus angle than male athletes. These factors 
are considered to be contributors of the increased likelihood of injury in females.32 Some 
research suggests that differences in training between males and females may lead to 
differences in injury rates.5,6  It has been found by Hewitt et al 3 that by implementing a 
program which incorporates flexibility, plyometrics, and weight training to increase 
muscle strength and decrease landing forces can decrease injury rates. That same study 
found that the incidence rate of injury for untrained females was 3.6 times higher 
compared to trained females and 4.8 times higher than that of the male control group. 
That was then compared to the trained female group which was only 1.3 times higher 
than the untrained male control group.3 That being said, other factors such as female sex 
hormones also may be a factor.7  
 Epidemiology 
 Female college aged athletes, specifically soccer and basketball players have been 
found to be more susceptible to ACL injuries in several cohort studies.33,34 Ireland stated 
that from 1990-1998, female soccer and basketball players experienced 2.29 to 2.89 times 
more ACL injuries than males in those same sports.33  The same study looked at 
noncontact ACL basketball injuries at 29 different colleges over 2 seasons of play and 
found that female athletes were 6.1 times more likely to sustain an ACL injury than 
males.33 A study by Hootman et al, reported that the four sports with the highest rates of 
ACL injury in college athletics were women’s gymnastics, basketball, and soccer, along 
with men’s spring football.35 Overall, rates of noncontact ACL tears range anywhere 
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from 2 to 10 times greater in female basketball and soccer athletes than males playing the 
same sports.3,33 
Knee Joint Laxity Assessment 
 In order to determine the amount of laxity in a ligament, special tests that are both 
precise and accurate need to be used. Several manual as well as mechanical ligamentous 
tests can be used for on field and clinical evaluations determining ACL laxity and also 
provide objective measurements. The most widely used manual tests for anterior knee 
laxity are the Lachman’s test, anterior drawer test and the lateral pivot shift test while the 
KT-1000 is one of the most common mechanical tests.  
 The Lachman’s test is performed with the patient laying in a supine position with 
their knee flexed at 20-25°.27 The examiner is positioned so that they have one hand 
grasping the tibia at the level of the tibial tuberosity and the other hand grasping the 
femur just above the condyles. As the examiner is supporting the weight of the leg and 
the knee is flexed at the correct angel, the tibia is pulled anteriorly while a posterior 
pressure is put on the femur in order to stabilize. A positive test is noted when there is an 
increase in anterior tibial translation compared with the opposite limb or if there is a lack 
of end feel.  The Lachman’s test has been found to be effective in 91% of acute and 100% 
of chronic ACL injuries preoperatively (n=50).36 
 The anterior drawer test is performed with the patient laying supine with the hip 
flexed at 45° and knee flexed at 45°.27 The examiner then sits on the end of the 
examination table in front of the involved knee while grasping the tibia just distal to the 
joint line with thumbs placed along the joint line on each side of the patellar tendon. The 
tibia is then pulled anteriorly and a positive test is noted when there is an increased 
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amount of anterior tibial translation compared to opposite limb or if there is a lack of end 
feel. It is important to remember that in order to get accurate results the hamstrings must 
be relaxed. The anterior drawer test has been found to be effective in 20% of acute and 
60% of chronic ACL injuries preoperatively (n=50).36  
 The lateral pivot shift test is performed with the patient laying supine with the hip 
flexed to 30°.27 The examiner is positioned standing laterally to the patient with the distal 
lower leg/ankle grasped while maintaining 20° of internal tibial rotation. The opposite 
hand of the examiner is then placed on the lateral portion of the leg superior to the joint 
line while increasing the force of internal rotation. While the test is being performed, 
internal rotation is maintained while also applying a valgus force to the knee and slowing 
flexing it. A positive test is noted when then tibia’s position on the femur is reduced as 
the knee flexed in the range of 30°-40° or if during extension there is anterior subluxion 
of the tibia. The pivot shift test has been found to have a specificity of 0.96 and a 
sensitivity of 0.60.27 All three of the manual tests have modifications to compensate for 
differences in size ratios between examiner and patient.      
Clinical assessments and manual ligamentous tests are the most common form of 
identifying ACL deficiencies. However, sometimes subtle changes are more easily noted 
with the use of mechanical devices because of their ability to provide objective results. 
The KT-1000 is one of the mechanical devices used to assess knee joint laxity. In order to 
use the KT-1000 it is applied to the anterior aspect of the tibia, parallel to the line of the 
tibial tuberosity while the patient is laying supine.28 The patient’s knees are placed into 
20-30° of flexion by putting a thigh support under the distal femur. Tibial rotation is 
placed at neutral with the help of a foot support which prevents external tibial rotation. 
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There are two Velcro straps that wrap around the proximal and distal ends of the tibia at 
points where the arthrometer is able to have proper positioning. The position puts the 
patellar sensor over the patella and joint line indicator directly in line with the joint line. 
Pressure is then applied to the sensor pad and is given in either an anterior or posterior 
direction with forces of 15, 20 and 30 lbs.28 Each different level of force is indicated by 
audible tones. Displacement is then recorded in millimeters as indicated by a dial on the 
arthrometer. According to a meta-analysis by  van Eck, the KT-1000 was found to have a 
sensitivity of .93, a specificity of .93, accuracy of .93 and positive predictive value of 6.9 
for diagnosing ACL rupture.34  
Figure 6: MLH Physio KT-1000 
  
MLH Physio KT-1000. Google Images. 
https://www.google.com/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&ua
ct=8&ved=0CAcQjRxqFQoTCK7DvabJlskCFYnZJgodMPMDCQ&url=https%3A%2F
%2Fwww.youtube.com%2Fwatch%3Fv%3Dpn76MHIHOWc&psig=AFQjCNF-
mWb5tfDqYWaN8v_-PB_gS16EfQ&ust=1447819279960031. Accessed November 16, 
2015.  
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 Isokinetic Muscle Training   
In isokinetic testing, females have been reported to have a mean hamstring-to-
quadriceps ratio of less than 0.5.6 Hamstring-to-quadriceps ratios of 0.5 or less have been 
reported to possibly assist in anterior tibial translation and therefore may increase the 
occurrence of ACL injuries.22 An example of an Isokinetic testing machine is the Biodex 
System 4 (Biodex Medical Systems, Shirley, NY). The Biodex has been reported to be a 
reliable tool for measuring isokinetic torque production up to 300 degrees/second 
(ICC=0.99, CV < 2%).37 
Figure 7: Movement lab – NeXt Move – Faculty  
 
Movement lab – NeXt Move – Faculty. Google Image. 
http://www.ntnu.edu/documents/221360533/221370823/MedFak_ganglab_fotografGeir
Mogen(5).jpg/252e279d-e4ff-4ebe-ac4b-b0ebe8eda77b?t=1392730084700. Accessed 
November 16, 2015. 
The Biodex measures peak torque by computing the amount of pressure generated 
through the entire range of motion at the selected speed (degrees/sec). Isokinetic 
machines do this by using a combination of hydraulic, pneumatic, and mechanical 
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pressure systems to produce a constant velocity of motion.23,38 That information is then 
used to compute force or power.35 Isokinetic testing has high clinical value because it 
allows clinicians to allow for passive motion, isometric and isotonic strengthening, 
eccentric and concentric muscle action, and open chain exercise.35  
Female Menstrual Cycle Hormones 
 The main hormones associated with a naturally occurring menstrual cycle are 
progesterone, estradiol, Luteinizing Hormone (LH), and, Follicle Stimulating Hormone 
(FSH). Estradiol and progesterone are primarily produced by the ovaries and corpus 
luteum, while LH and FSH are produced by the hypothalamus and pituitary gland.39 
These hormone levels vary across the menstrual cycle based on the menstrual phase. 
There are three phases associated with a normal menstrual cycle which are listed as 
follows: the follicular phase, the ovulatory phase, and the luteal phase. In this study blood 
assays were used to determine hormone levels in each of the three menstrual cycle 
phases. The progesterone assays have intra and inter assay CVs of 2-12% and 5-12%, 
respectively and a lower limit of detection of 0.11ng/mL. The estradiol-17β assays have 
intra and inter assay CVs of 5-11% and 6-12%, respectively and a lower limit of 
detection of 7.2pg/mL. Relaxin RIA kits were obtained from Phoenix Pharmaceuticals, 
Burlingame, California. The Relaxin assays have intra and inter assay CVs of 5-7% and 
12-15%, respectively and a lower limit detection of 36-53 pg/assay. 
 During the follicular phase, most hormone levels begin to increase in preparation 
for ovulation. Normal estradiol levels range from 25-75 pg/mL in this phase while normal 
progesterone levels are <1.5ng/mL. Progesterone is the only hormone that does not spike 
immediately before or at ovulation. LH and FSH have normal levels of 3-20 mlU/mL 
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during this phase with the highest levels occurring at ovulation. LH and FSH are the main 
gonadotropin hormones that lead to the release of the egg from the mature follicle.39  
 Once the ovulatory phase occurs, levels in estradiol peak and then dramatically 
drop with a normal peak of >200 pg/mL. The drop in estradiol levels occurs with the start 
of the luteal phase when progesterone levels begin to increase. Progesterone levels are 
normally >5 ng/mL during the ovulatory phase but begin to rise because of the release of 
progesterone from the corpus luteum. The corpus luteum is a small body that develops 
within a ruptured ovarian follicle following ovulation.39 Normal levels of FSH during this 
phase peak at >25 mlU/mL and then drop at the start of the luteal phase. LH follows a 
similar pattern as it peaks at >20 mlU.mL and then drops once the luteal phase begins.  
 The final phase of the menstrual cycle is the luteal phase. During this phase 
estradiol levels return to a normal level of 25-75 pg/mL. Progesterone levels are highest 
during this phase because of the production that comes from the corpus luteum and are 
normally >15 ng/mL. These high levels inhibit the production of LH and FSH until the 
end of this phase when FSH begins to rise again in order to initiate the maturation of new 
follicles for the next cycle.39 Normal values for LH are 3-20 mlU/mL while normal 
values for FSH are <25 mlU/mL. The figure below illustrates the fluctuation of hormones 
across the entire menstrual cycle.      
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Figure 8: Hormone Levels During Menstrual Cycle 
 
Hormone Levels During Menstrual Cycle. Google Images. 
https://www.google.com/search?q=hormone+levels+during+menstrual+cycle&espv=2&b
iw=1517&bih=714&source=lnms&tbm=isch&sa=X&ved=0CAYQ_AUoAWoVChMI68
CXqq-QyAIViII-
Ch2TbwcR&dpr=0.9#tbm=isch&q=hormone+levels+during+menstrual+cycle+luteal&i
mgrc=OpyNuxb0EUaxlM%3A September 24, 2015. 
 In summary, there are a number of different anatomical and physiological factors 
that can affect a person’s likelihood of sustaining an ACL injury, especially in the female 
population. It is important to remember that female athletes are up to 10 times more 
likely to injure their ACL and therefore it is necessary for additional research to be 
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completed to determine which risk factors can be modified to decrease ACL injury 
incidence.2,3,33   
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CHAPTER 3 
Methods 
 Participants (n=50) were asked to participate in three separate study visits over the 
course of one menstrual cycle. Each of the three visits coincided with different phases of 
their menstrual cycle.  The first visit was between days 1 and 5 of the menstrual cycle in 
order to coincide with the follicular phase when estrogen and progesterone are low.  Visit 
number two was performed within 48 hours of the onset of menses. The final visit was 7 
days after the ovulation visit and coincided with the luteal phase. Blood tests were 
performed at all of the visits to confirm the menstrual cycle phase participants were in. 
All study visits are outlined in Table 1. 
Table 1. Outline of the study visits 
Procedure  Enrollment Follicular Ovulation Luteal 
Informed 
Consent 
Signed informed 
consent X    
Questionnaires Medical History  X    
Anthropometrics Height, Weight  X   
Blood Tests 
Estrogen, Progesterone, 
Relaxin 
 X X X 
Muscle Strength  
Uni-lateral Isokinetic 
Protocol (Biodex) 
 X X X 
Laxity Testing 
Passive displacement 
and maximal 
displacement tests 
 X X X 
 
Recruitment and Subject Description 
College-aged, physically active females (n=50) were recruited from South Dakota 
State University.  Recruitment was completed through on-campus advertising and 
through meetings with classes in the Department of Health and Nutritional Sciences. 
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Twenty-five females that were taking oral contraceptives were recruited and twenty-five 
females that were not taking oral contraceptives were recruited. 
Inclusion and Exclusion Criteria 
Inclusion Criteria for Potential Participants  
An initial questionnaire was administered at the enrollment visit to determine whether 
the menstrual status was regular, and the participant was physically active at least 3 times 
per week. 
Inclusion Criteria for Non-contraceptive Group 
Participants were active College aged females with regular menstrual cycles.   
Inclusion Criteria for Contraceptive Group 
Participants were active College aged females with regular menstrual cycles 
taking a monophasic oral contraceptive. 
Exclusion Criteria for Non-contraceptive and Contraceptive Group  
Participants were excluded if they were men, women with amenorrhea, college 
aged females who are not taking oral contraceptives as directed, college aged females not 
taking monophasic contraceptives, history of knee injury within last 6 months or prior 
ACL reconstruction. Participants with irregular menstrual cycles were excluded as to 
eliminate hormonal variability that women with irregular cycles may exhibit. 
Methods to Increase Participation 
Participants were given the torque curve data from their Biodex protocol which 
could help them to identify functional deficits that could be improved with training. In 
addition to the information from Biodex testing, participants received twenty dollars per 
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experimental visit for a total of sixty dollars at the conclusion the of experiment. 
Participant data was kept confidential and stored in a secure location. 
Study Protocol 
Enrollment Visit 
 On the day of the initial visit, an informed consent (Appendix A) was obtained 
along with a medical history questionnaire that asked about personal and family history 
of diseases and chronic injury as well as information regarding the participant’s 
menstrual cycle (Appendix B). From this information, potential participants were 
screened for conditions that may exclude them from participation.  
Menstrual Cycle Monitoring 
 All participants were asked to contact the study coordinator on the first day of 
their menstrual cycle to schedule an appointment for their first testing session within 72 
hours of the onset of menses (Appendix C,D,E). The participants who were taking oral 
contraceptives had their subsequent visits on cycle day 14 and cycle day 21. Participants 
who were not taking oral contraceptives were asked to take a home ovulation test every 
day beginning at day 10. When a positive test occurred, the participants were asked to 
contact the study coordinator and set up a visit within 48 hours (Appendix F). A reminder 
telephone call was made to each participant on day 10 of their cycle to improve 
compliance. This helped to determine the day that ovulation occurred in each of the 
women to aid us in determining an individualized testing schedule for each of the 
participants. The final visit took place 7 days after the ovulation visit. During the testing 
period, participants had their menstrual cycle phase confirmed through blood testing.  
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Experimental Period 
 Participants were asked to complete testing over the course of one menstrual 
cycle.  Participants were asked to complete a DEXA scan, Biodex isokinetic test, a knee 
joint laxity exam, and provide blood samples. Specific details and rationale regarding 
these tests are given below. (Appendix A) 
Anthropometrics 
 Anthropometric measurements were taken during the first experimental session. 
Height was measured to the nearest 0.5cm using a portable stadiometer (Seca Model 225) 
and weight was measured to the nearest 0.1kg using a digital scale (Seca Model 770).   
Blood Draws 
 A venipuncture was performed by a trained phlebotomist. The blood was 
analyzed for estradiol, progesterone, and relaxin using radioimmunoassay (RIA). 
Estradiol-17β and progesterone double antibody RIA kits were obtained from MP 
Biomedical in Solon, OH. All the blood assays were analyzed using radioimmunoassays 
in the Animal Science lab on campus at South Dakota State University.  
Biodex 
 To perform the Biodex isokinetic testing, the subject was seated with their 
shoulders and waist strapped to the chair. The participant’s ankle was secured to the leg 
holder with a Velcro strap. Once the participant was properly positioned, they went 
through a series of familiarization repetitions to get accustomed to the machine. The 
performance trial consisted of 5 isokinetic quadriceps extension and hamstring curl 
repetitions at 60 degrees per second, 5 repetitions at 180 degrees per second, and 5 
repetitions at 300 degrees per second. Each series of repetitions was separated by a 30 
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second rest period. This testing was used to determine quadriceps strength. After the 
performance trials, a fatigue protocol was prescribed to each participant. The fatigue 
protocol was done at 180 degrees per second and required the participants to perform 
knee flexion and extension as many times as they could until they dropped below 50 
percent of their max torque for three consecutive repetitions based on information gained 
from the performance test. 
KT 1000 
 To perform laxity testing using the KT 1000 knee arthrometer, the subject was 
placed in a comfortable supine position. An adjustable thigh support platform was placed 
under both legs just proximal to the popliteal space. A foot support platform was then 
placed under both feet with the patient’s feet located in a position that allowed the knee to 
be in a neutral position. Next, the knee was placed in a neutral quadriceps or 30 degree 
flexion position using the adjustable thigh support. The thigh was then secured using the 
Velcro strap and the arthrometer was placed on the anterior aspect of the tibia with the 
joint line arrow bisecting the joint line. Three separate testing protocols were used to test 
specific characteristics of the ACL. A maximal displacement test was performed to 
quantify that amount of laxity in the joint and to determine the endpoint with the knee in 
30 degrees of flexion. KT-1000 measurements were done prior to and immediately 
following the Biodex testing to assess the effect of muscle fatigue on knee joint laxity. 
All measurements were performed by the same certified athletic trainer using the KT-
1000 knee arthrometer.  
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Protection of Human Subjects and Treatment 
This protocol was reviewed and approved by the Institutional Review Board 
(Appendix G) at South Dakota State University. All records were double entered into a 
database on a computer that is not connected to the internet. All data and computers were 
stored in a card swipe protected facility. 
Table 2. Outcome Measures 
Outcome Modality/Unit 
Follicular 
Phase Norms 
Ovulatory 
Phase Norms 
Luteal Phase 
Norms 
Torque Newton-Meters NA NA NA 
Laxity Millimeters NA NA NA 
Estradiol Radioimmunoassay 25-75pg/mL >200pg/mL 25-75pg/mL 
Progesterone Radioimmunoassay <1.5ng/mL >2ng/mL >4.5ng/mL 
Relaxin Radioimmunoassay NA NA NA 
NA = not available 
Sample Size and Power 
 The sample size calculations were based on the number of subjects per group for 
the contraception and non-contraception groups to test for differences in isokinetic 
quadriceps strength. (Hypothesis 1); and knee joint laxity, (Hypothesis 2).  In order to 
take into account differences between the oral contraception and non-oral contraception 
groups (Hypothesis 3), we could use the calculated sample size per group and include 
contraception group as a covariate in the analysis, or we could choose to enroll the 
number of participants per group for contraception. We chose to use the more 
conservative approach of enrolling based on contraception group size because of the large 
hormonal differences between the two groups. This sample size also will allow us to test 
for the hormonal group-by-menstrual phase interaction on the neuromuscular function 
(Hypothesis 3). 
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 Hypothesis 1: The sample size estimate for hypothesis 1 is based on the number of 
participants required to detect differences in isokinetic quadriceps strength among 
menstrual cycle phases. This measurement has been implicated as a potential risk factor 
for ACL injuries.22 In order to calculate this sample size, we used data from Hewett et al.6  
Assuming a 20% withdrawal rate, we will recruit 50 women for the project. This is a 
conservative based on detecting differences between two means calculate on independent 
observations and does not consider that we will be taking repeated measures on the same 
participants. 
 Hypothesis 2: The sample size for hypothesis 2 is based on the number of 
participants required to detect differences in mean anterior knee joint laxity, joint 
stiffness, and joint moments among different phases of the menstrual cycle. In order to 
calculate the sample size for knee joint laxity, we used data from Deie et al. 2002.13 The 
mean knee joint laxity was 4.7 mm (SD=0.8). A sample size of 40 will be necessary to 
detect an 11 percent difference between means. Similarly to hypothesis 1, we will recruit 
50 women to test hypothesis 2.  This is a conservative estimate based on detecting 
differences between two means calculated on independent observations and does not 
consider that we will be taking repeated measures on the same participants.  
Hypothesis 3:  The sample size for hypothesis 3 is based on the number of 
participants in the oral contraception and non-oral contraception groups required to detect 
differences in hamstring-to-quadriceps ratio, and joint laxity. Sample sizes for each of the 
variables were calculated using the same data used in hypotheses 1 and 2. Given the large 
hormonal variation that exists between individuals who are and are not on oral 
contraception, we expect these to be physiologically reasonable differences.  
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The sample size per group needed to detect a difference between two means was 
calculated using the equation below. 
N =
[2(𝑆𝐷)2 (𝑍𝛼
2
+  𝑍𝛽)
2
(𝜇1 −  𝜇2)2
 
SD = the standard deviation of the outcome variable 
𝜇1 = the mean of one of the contraception groups 
𝜇2 = the mean of the other contraception group 
(Zα/2 +Zβ)
2  = reflects the coordinates on the normal distribution that correspond to the 
specified type 1 and type 2 errors.  Our hypotheses will be tested using a 2-sided p value 
at a significance level of 0.05 and 80% power 
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CHAPTER 4 
Results 
 Fifty participants were enrolled in the study and signed informed consents. Of 
those, 25 were using oral contraception and 25 were not. In the contraception group, one 
participant did not complete all three visits due to problems with blood sample 
acquisition and therefore was excluded from the analysis. Additionally, in the non-
contraceptive group, 3 participants did not ovulate and therefore were excluded from the 
analysis. There was no significant difference in baseline characteristics between groups 
(Table 3).  
Table 3. Participant Characteristics 
 Non-Contraception 
(n=22) 
Contraception 
(n=24) 
P Value* 
Age (Years) 20.39 [18.6-25.1] 20.81 [19.4-23.2] NS 
Height (cm) 167.09 ± 6.45 169.87 ± 6.91 NS 
Weight (kg) 63.82 ± 8.84 65.70 ± 11.4 NS 
*P-Value for the difference between contraception and non-contraception groups 
Height and Weight are given as mean ± SD 
Age is given as mean [range] 
 
 Isokinetic tests showed that peak torque levels were significantly lower at 60, 180 
and 300˚/sec during the follicular phase as compared to the ovulatory and luteal phase 
(Table 4) (Figure 9). This finding was consistent between groups and within group.   
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Table 4. Outcome Measures and Hormonal Concentrations by Visit and Contraception 
Group 
  Non-Contraception 
(n=22) 
Contraception 
(n=24) 
P Value* 
Visit 1: Follicular Phase    
 Rested Laxity 6.4 ± 2.6 7.0 ± 2.9 0.5 
 Fatigued Laxity 6.9 ± 2.0 7.0 ± 2.4 0.9 
 60 Peak Torque** 148 ± 30 155 ± 24 0.4 
 180 Peak Torque** 95 ± 18 102 ± 18 0.2 
 300 Peak Torque** 76 ± 18 81 ± 14 0.2 
 Estradiol (pg/ml) 67.6 ± 20.2 45.8 ± 20.9 <0.001 
 Progesterone (ng/ml) 0.06 ± 0.03 0.04 ± 0.04 0.3 
 Relaxin (pg/ml) 29.8 ± 19.4 27.2 ± 15.7 0.6 
Visit 2: Ovulation Phase    
 Rested Laxity 6.1 ± 2.1 6.6 ± 2.5 0.5 
 Fatigued Laxity 6.4 ± 2.2 6.3 ± 2.4 0.9 
 60 Peak Torque** 156 ± 28 159 ± 24 0.6 
 180 Peak Torque** 102 ± 20 110 ± 18 0.1 
 300 Peak Torque** 81 ± 16 88 ± 15 0.1 
 Estradiol (pg/ml) 134.5 ± 64.5 36.0 ± 18.8 <0.001 
 Progesterone (ng/ml) 1.2 ± 2.6 0.05 ± 0.06 0.04 
 Relaxin (pg/ml) 26.7 ± 18.4 27.6 ± 16.5 0.9 
Visit 3: Luteal Phase    
 Rested Laxity 6.2 ± 2.2 6.1 ± 2.0 0.8 
 Fatigued Laxity 6.3 ± 1.7 6.5 ± 2.1 0.6 
 60 Peak Torque** 153 ± 30 155 ± 22 0.6 
 180 Peak Torque** 107 ± 20 113 ± 18 0.3 
 300 Peak Torque** 83 ± 16 87 ± 14 0.4 
 Estradiol (pg/ml) 154.1 ± 62.1 33.7 ± 15.3 <0.001 
 Progesterone (ng/ml) 3.4 ± 3.5 0.05 ± 0.08 <0.001 
 Relaxin (pg/ml) 31.3 ± 21.3 27.0 ± 14.6 0.4 
*P-Value for the difference between contraception and non-contraception groups 
All values are given as mean ± SD 
**Torque values are reported in Newton-Meters (NM) 
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Figure 9: Isokinetic Testing 60˚/sec 
 
Bars with similar letters are different at p<0.05 
 
Figure 10: Isokinetic Testing 180˚/sec 
 
Bars with similar letters are different at p<0.05 
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Figure 11: Isokinetic Testing 300˚/sec 
 
 
Bars with similar letters are different at p<0.05 
 
 Our findings indicate that there was no significant difference in knee joint laxity 
in either the non-contraceptive group or oral contraceptive group across the menstural 
cycle. (Table 4)  
 Results of blood assays showed that there was no significant difference between 
groups  for relaxin concentration. (Table 4) There were significant differences with 
estrodial and progesterone concentration between groups. (Table 4) We found that 
estrodiol (p<0.001 and p<0.001) and progesterone (p<0.04 and p<0.001)  concentrations 
were lower during the ovulatory and luteal phases in the oral contraceptive group. The 
inclusion of estodiol, progesterone, and relaxin in the statistical models had no signifcant 
affect on muscle strength or knee joint laxity for either group. (Table 4)  
  
AB
A
B
74
76
78
80
82
84
86
88
Follicular Phase Ovulation Phase Luteal Phase
P
ea
k
 T
o
rq
u
e 
(N
M
) 
(3
0
0
˚/
se
c)
Isokinetic Testing  300˚/sec 
38 
 
CHAPTER 5 
Discussion 
 The primary purpose of this study was to analyze the neuromuscular changes in 
females during different phases of the menstrual cycle. 
Muscle Strength 
The first aim of this study was to analyze the muscle strength of the quadriceps in 
females throughout the three phases of the menstrual cycle. It was hypothesised that 
quadriceps strength would decrease as estrogen increased during the menstrual cycle. 
Upon analysis of our results it was found that isokinetic peak torque at 60°/sec, 180˚/sec, 
and 300˚/sec was lowest during follicular phase. Testing at the same parameters during 
the ovulation and luteal phases showed significant increases in peak torque compared to 
the follicular phase. We rejected our hypothesis because during the follicular phase, 
which has the lowest estradiol concentrations, peak torque was also lowest.  
Strength Differences throughout the Menstrual Cycle 
Sarwar et al reported that the greatest muscle strength was evident during the mid-
cycle or ovulation phase and the lowest muscle strength was found in the luteal phase.7 
This contradicts what was found in the current study. We found that the greatest muscle 
strength was in the luteal phase. Our results at 60˚/sec, are similar to Sarwar et al because 
they show an insignificant peak muscle torque decrease from the ovulatory to luteal 
phase. Phillips et al, found a correlation between menstrual cycle phase and measured 
muscular force. The study reported a significant increase in maximum voluntary force 
during the follicular phase while estrogen levels were rising. However, this study used a 
non-weight bearing muscle (adductor pollicus).41  
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In a systematic review by Constantini et al, it was reported that muscle strength 
does not appear to fluctuate significantly during the menstrual cycle. Constantini et al 
researched the connection between strength differences and menstural cycle phase 
finding that a majority (5) of studies found an insignificant correleation. While only three 
studies reported a significant change between muscle strength and menstrual cycle 
phase.12 Constantini attributed the differences to methodological quality and individual 
participant variability. Another study by Janse de Jong et al42 also demonstrated no 
correlation between muscle strength and menstual cycle phase.  
Knee Joint Laxity 
 The second aim of this study was to analyze knee joint laxity in females 
throughout the three phases of the menstrual cycle. Our hypothesis was that knee joint 
laxity would increase during the follicular phase of the menstrual cycle. Our results did 
not show a significant change between phases of the menstrual cycle. However, it should 
be noted that our findings did show an insignificant trend that supported our hypothesis. 
In our results (Table 4) knee joint laxity measurements changed slightly from the 
follicular phase compared to the ovulatory and luteal phases. In studies completed by 
Karageanes et al,18  Van Lunen et al, 17  Beynnon et al, 19 Eiling et al, 43 and Belanger et 
al 44 it was concluded that there were no significant changes in knee joint laxity across the 
menstrual cycle. 
 However, there are also studies that did report significant changes in knee joint 
laxity across the menstrual cycle. In one study done by Heitz et al.14 it was concluded 
that; “female ACL laxity significantly increases in conjunction with surging levels of 
estrogen and progesterone during the normal menstrual cycle.” However this could be 
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due to the timing of the blood draws and joint laxity testing. In the Heitz study, blood 
draws and laxity tests were done more fequently compared to our study. Heitz et al14 
conducted joint laxity tests and blood draws on all seven subjects on nine different days 
throughout the menstrual cycle. This was done so that they could more accurately 
associate peak hormone levels with ACL laxity. While this is adds to the methodological 
quality, the amount of visits that were performed in the Heitz study would not have been 
feasible for our current study since we used 50 participants. With this in mind, further 
research should be done looking at larger sample sizes while using a method involving 
more than three blood draws.  
 Another study that found significant changes in knee joint laxity was completed 
by Deie et al.13 The researchers concluded that there is “a significant difference in the 
anterior displacement of the knee between the follicular phase and the ovulatory and 
luteal phases.” However, they also concluded that “there was no statistically significant 
relation between ACL laxity and the concentrations of female hormones.” The reason 
that they were unable to correlate the significant changes in joint laxity with 
concentrations of hormones was thought to be because they were unable to complete a 
sufficient amount of blood draws. Hormone levels were measured once per week (4 
times) so they concluded that they did not have sufficient evidence to properly monitor 
hormone fluctuations and thus have significant findings. This same argument could be 
used in our study as well since we only measured hormone levels three times and instead 
relied on self reported ovulation tests to direct the monitoring of each participant’s cycle. 
Another point worth noting is that in Deie et al 13 they used a KT-2000 arthrometer while 
we used a KT-1000. Both have 95% confidence intervals to support their use but the KT-
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2000 is newer and provides computer plotted X-Y graphs while measurements are 
taken.45,46 For this reason, small variations in measurements could occur. 
 Another study which found differences in knee joint laxity across the menstrual 
cycle was completed by Shultz et al.15 Their study concluded that: “estradiol, 
progesterone, and testosterone each contribute to changes in knee laxity across the cycle, 
and that this relationship is stronger when changes in hormone concentrations are 
compared with changes in knee laxity occurring approximately 3–4 days later.” 15 It was 
also noted that since each subject’s time delay varies, it is difficult to make a correlation 
between one sex hormone and all subjects. Our study did not consider a time delay in 
hormone response and thus we did not make adjustments based on that notion.   
Hormone Levels        
The third aim of this study was to analyze hormonal changes in estrogen, 
progesterone, and relaxin, throughout the menstrual cycle. Our hypothesis was that 
participants in the non-oral contraceptive group would show changes in quadriceps 
muscle strength and knee joint laxity compared to the oral contraceptive group. Our 
findings show that there are no significant differences between the oral contraceptive and 
non-contraceptive groups in regards to quadriceps muscle strength or knee joint laxity at 
any stage in the menstrual cycle.   
Strength Differences Between Groups 
 In reports by Sarwar et al and Hewitt et al, it was reported that there are between 
group significant changes in contractile and relaxing properties in skeletal muscle during 
the ovulatory phase.4,7 Both studies attribute these changes to rising estrogen levels. 
Hewitt et al 4 found that hamstring to quadriceps peak torque ratios are lower in the non 
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contraceptive population because of higher hormone levels. Sarwar et al 7 also reported a 
significant difference in muscle strength between contraceptive and non-contraceptive 
groups. Our results show an insignificant trend that peak torque was higher for the 
contraceptive group throughout the menstrual cycle but it wasn’t enough to show 
significance. The reason for inconsistent results could be due to different strength testing 
methods. In this study we used a Biodex with a built in fatigue protocol and Sarwar et al 
used a conventional strength testing chair with electrical stimulation. Differences could 
also be attributed to patient effort and conditioning. 
The results of the current study showed an insignificant trend in a relationship 
between increased estradiol concentrations and increased muscle strength in the non 
contraceptive group. This trend was also noted in a Sarwar et al study 7 in which they 
found that the highest estrogen levels occur just prior to ovulation and that the surge may 
be responsible for an increase in muscle strength at that time. More research needs to be 
completed to determine if muscle strength increases can be attibuted to an increase in 
estrogen levels or an increase in progesterone levels. 
Hormone Fluctuations  
There were significant differences found in estradiol and progesterone levels 
throughout the menstrual cyle with estrodiol and progesterone levels being lower in the 
ovulatory and luteal phases in the oral contraceptive group. These results support other 
studies that have been mentioned previously.4,7,12 Relaxin is one female sex hormones 
that is not extensively researched. One of the goals of this study was to see if we could 
correlate increased relaxin levels with increased joint laxity findings. The results of our 
study suggest that there were no significant correlations with relaxin and knee joint 
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laxity. A study by Dragoo et al 47 researched the differences in female sex hormone levels 
between two groups, oral contraceptive and non-contraceptive and how they correlated 
with serum relaxin concentration. It was found that there is a positive correlation between 
progesterone levels and serum relaxin concentration. They concluded that the non 
contraceptive group had higher serum relaxin concentration levels compared to the 
contraceptive group. 47 This contradicts what was found in our study because we found 
significant differences between progesterone levels between the two groups and 
significant differences in relaxin levels were not noted. The reason for the difference in 
findings could be due to of the variance in the number of participants. The Dragoo study 
reported having 169 participants compared to the 50 that were involved in the current 
study.  
In a study completed by Arnold et al 20 it was reported that there were no 
correlations found between knee joint laxity and serum relaxin concentration. They 
studied the differences between men and women and found that women had higher serum 
relaxin levels but did not find significant changes in knee joint laxity between groups.20 
This is similar to results of the current study, although it was insignificant, we did see a 
small trend which showed the non contraceptive group had higher serum relaxin 
concentration when compared to the oral contraceptive group but again no changes in 
knee joint laxity were noted in either group.         
Limitations  
 There are several limitations that should be noted in this study, including: small 
number of data points, no monitoring of oral contraceptive use, and the potential for 
participant drop out. It was found in some studies that additional visits, provided more 
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accurate hormone monitoring which led to more specific findings.14 Perhaps scheduling 
more visits would yield significant findings.  
 The KT-1000 is a clinically relevant tool with strong research 46 to support the 
use. According to a meta-analysis by van Eck et al,34 the KT-1000 was found to have a 
sensitivity of .93, a specificity of .93, accuracy of .93 and positive predictive value of 6.9 
for diagnosing ACL rupture. The KT-2000 has been shown to be quite reliable as well 
with a 95% confidence interval for reliability estimates.45 However, it could be 
scientifically beneficial to use an even more valid arthrometric device to assess knee joint 
laxity in the future. There are many variables that could change the outcome of the 
readings for the KT-1000 from patient to patient. Examples of these variables are: patient 
positioning, equipment positioning, and test re-test reliability. We attempted to eliminate 
these variables as much as possible by completing an interrater reliability test with our 
researchers and used only one tester for every participant, who was blinded to group 
assignment. However, small errors could still occur.     
Future Research 
Future research should include more scheduled visits and tests for each participant 
group throughout the menstrual cycle. That change may lead to more significant findings 
related to muscle strength or knee joint laxity across the menstrual cycle.7,15 Using a more 
scientifically reliable method to assess knee joint laxity, may account for the minute 
changes that previously went unnoticed. Future studies should also look into the 
underlying cause of the decrease in muscle strength that was found to occur during 
menstruation. Also, more studies need to be done to see if hormonal surges lead to 
delayed knee joint laxity and quadriceps muscle strength. 
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Conclusion 
 Our results show that muscle strength is lowest during the follicular phase of the 
menstrual cycle and muscle strength and knee joint laxity are independent of hormone 
level fluctuations. Therefore additional research is necessary to understand the decrease 
in muscle strength during menstruation.  
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Appendix A 
Consent to Participate in a Research Project 
South Dakota State University 
Brookings, SD 57007 
 
Department of: Ethel Austin Martin Program in Human Nutrition 
Project Director: Lee Weidauer, PhD  Phone Number: (605) 688-4630 
E-mail: Lee.Weidauer@sdstate.edu   Date _____________________ 
 
Please read (listen to) the following information:  
1. This is an invitation for you to participate in a research project under the direction 
of Dr. Lee Weidauer.  
2. The project is entitled The Role of the Menstrual Cycle in Neuromuscular Risk 
Factors for ACL Injuries.  
3. The purpose of the project is to determine the change in neuromuscular 
performance throughout the menstrual cycle in college-aged females and the 
effect of hormonal contraception on these changes.  
4. If you consent to participate, you will be involved in the following process which 
will take about 3 hours of your time:  
Questionnaires  
You will be asked to complete a medical history questionnaire. This questionnaire 
will ask you to list any medications you are taking and also ask you about certain medical 
conditions you may or may not have. Additionally, you will be asked to complete a 
questionnaire that will ask you about certain symptoms related to your menstrual cycle 
that you may or may not be experiencing.  
Height and Weight  
We will measure your height and weight without shoes and wearing light 
clothing.  
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Grip Strength  
We will measure your grip strength using a device that you will be asked to 
squeeze as hard as you can for 3 seconds.  
Quadriceps Angle  
Quadriceps angle will be measured to the nearest degree using a goniometer. 
Quadriceps angle is the angle formed by a line connecting the anterior, superior, iliac 
spine to the patellar midline and then patellar midline to the midline of the tibial tubercle.  
Body Composition  
Dual-Energy X-Ray absorptiometry (DXA) scans will be completed on the EA 
Martin Program’s mobile unit. The scan takes approximately 3 minutes to complete and 
provides a measure of body composition.  
24 Hour Diet Record  
You will be asked to complete a 24 hour diet log. Diet logs will be completed 
online using ASA24 software. The software uses a system that allows you several 
different chances to log everything you ate on a given day to ensure high quality dietary 
data is collected.  
Blood Tests  
A small needle will be used to draw 10ml of blood from a vein in your arm by a 
trained phlebotomist. The blood will be analyzed for estradiol, progesterone, and relaxin 
using radioimmunoassay.  
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Leg Strength  
You will be asked to complete a series of leg exercises. You will be asked to push 
as hard as you can against the machine while the speed of your movement is limited to 
60, 180, and 280 degrees per second.  
Joint Laxity  
We will measure the amount of movement in your knee using a KT 1000. The KT 
1000 is a non-invasive and safe method to measure movement in the knee. During this 
test you will be asked to lie flat on your back while relaxing the muscles in your leg  
5. Participation in this project is voluntary. You have the right to withdraw at any 
time without penalty and doing so will not affect you in any way. If you have any 
questions, you may contact the project director at the number listed above.  
6. You may experience lower extremity muscle fatigue and soreness from the 
isokinetic testing. You may experience discomfort and possible bruising at the site 
of your blood draw. You may feel uncomfortable providing some information to 
us and can decide if there is a question you do not want to answer. You will be 
exposed to a small amount of radiation during the whole body DXA scan. A total 
body DXA has a radiation dose of 0.35mrem. This is lower than the radiation 
dose of a transcontinental flight (5mrem).  
7. There are no direct benefits to you as a result of participation in this study; 
however, you will be given data regarding body composition and leg strength that 
might help you in making positive lifestyle decisions.  
8. As a thank you for your participation, you will be given 60 dollars as a thank you 
for your participation.  
9. Your responses are strictly confidential. When the data and analysis are presented, 
you will not be linked to the data by your name, title or any other identifying item.  
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As a research participant, I have read the above, have had any questions answered, and 
agree to participate in the research project and acknowledge that I have received a copy 
of this form for my information.  
Participant's Signature ______________________________ Date __________  
Project Director's Signature __________________________ Date __________  
If you have any questions regarding this study you may contact the Project 
Director. If you have questions regarding your rights as a participant, you can 
contact the SDSU Research Compliance Coordinator at (605) 688-6975 or 
SDSU.IRB@sdstate.edu. 
 
This project has been approved by the SDSU Institutional Review Board, 
Approval No.: IRB-1411007-EXP 
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Appendix B 
 
ENROLLMENT FORM 
 
 
Name:    DOB:   Participant ID:    
Telephone Number:    Email Address:     
Does the study staff have permission to send text messages to remind you of upcoming 
visits? YES       NO 
Race:  White   Black   American Indian/Alaska Native   Asian or Pacific Islander
 Unknown 
Height:  Weight:  BMI:    
Have you suffered any lower extremity injury in the past 6 months? YES 
 NO 
Have you ever suffered an injury to your anterior cruciate ligament (ACL)?   YES 
 NO 
How many days per week do you perform at least 30 minutes of physical activity? 
    
What was the first day of your last menstrual period?       
Do you have a regular menstrual cycle? (Every 21 to 35 days)   YES 
 NO 
Are you currently taking oral contraception?  YES  NO 
 If yes, what type?       
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List of monophasic oral contraceptives: Alesse, Apri, Aviane, Balziva, Brevicon, 
Demulen 1/35, Demulen 1/50, Femcon, Junel, Kariva, Lessina, Levlen, Levlite, Levora, 
Lo/Ovral, Loestrin, Lutera, Marvelon, Mercilon, Microgestin, Microgynon, Mircette, 
Modicon, MonoNessa, Necon, Norinyl, Notrel, Ogestrel, Ortho-cept, Ortho-cyclen, 
Ortho-Novum, Ovcon, Ovral, Ovranette, Portia, Seasonale, Seasonique, Sprintec, Yaz, 
Yasmin, Zovia 
 
 
PHYSICAL ACTIVITY READINESS QUESTIONNAIRE (PAR-Q) 
Name:       Date:      
 
 Questions Yes No 
1 Has your doctor ever said that you have a heart condition and that 
you should only perform physical activity recommended by a 
doctor? 
  
2 Do you feel pain in your chest when you perform physical 
activity? 
 
  
3 In the past month, have you had chest pain when you were not 
performing any physical activity? 
  
4 Do you lose your balance because of dizziness or do you ever 
lose consciousness? 
  
5 Do you have a bone or joint problem that could be made worse by 
a change in your physical activity?  
  
6 Is your doctor currently prescribing any medication for your 
blood pressure or for a heart condition? 
  
7 Do you have ANY other reason why you should not engage in 
physical activity? 
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Appendix C  
 
MEDICAL HISTORY QUESTIONNAIRE 
 
Name:      Participant ID:   Visit 
Date:    
 
 
Are you currently taking any medications (initial visit only)? YES NO 
 If Yes, please list below. 
 
Medication Reason 
  
  
  
  
  
 
Do you have any of the following conditions (Initial Visit Only)? (Check all that apply) 
 
 Acid Reflux (Heartburn)  Chronic Low Back Pain 
 Alcoholism  Depression 
 Allergies  Diabetes Type 1 
 Anxiety  Diabetes Type 2 
 Asthma  High Blood Pressure 
 Atrial Fibrillation  Irritable Bowl Syndrome 
 Cancer  Migraines 
 Coagulation (bleeding) 
problem 
 Low Bone Density or Osteoporosis 
 High Cholesterol  Thyroid Problem 
 Heart Disease  Kidney Disease 
 Blood Clots  Osteoarthritis 
 Tuberculosis  Rheumatoid Arthritis 
 Emphysema  Anemia 
 Hernia  Muscular Dystrophy 
 
Do you currently use tobacco (Initial Visit Only)? YES  NO 
 
Do you currently use alcohol (Initial Visit Only)? (circle the response that best describes 
your alcohol use) 
 
NEVER RARELY (1-2 Drinks/month)     SOCIALLY (1/week most weeks)    
FREQUENTLY (>2/week) 
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Appendix D 
 
MENSTRUAL SYMPTOM QUESTIONNAIRE 
 
Name:      Participant ID:  Visit Date: 
  
 
Visit Phase: Follicular Ovulation Luteal   
 
Answer the following questions based on how you have felt for the past 24 hours: 
 
1. I feel more irritable than normal     YES  NO  
2. I am experiencing menstrual cramps    YES  NO 
3. I am feeling more depressed than normal    YES  NO 
4. I am experiencing more stomach pain than normal  YES  NO 
5. I get tired more easily      YES  NO 
6. I am taking a prescription for menstrual pain   YES  NO 
7. I am feeling weak or dizzy     YES  NO 
8. I am feeling tense or nervous     YES  NO 
9. I am experiencing diarrhea     YES  NO 
10. I am experiencing backaches or lower back pain   YES  NO 
11. I am taking OTC medication for pain    YES  NO 
12. I am experiencing pain in my breasts    YES  NO 
13. I am using heat to treat my abdominal and/or back pain  YES  NO 
14. I am experiencing constipation     YES  NO 
15. I am experiencing muscle spasms in my legs   YES  NO 
16. I am feeling more bloated than normal    YES  NO 
17. I am feeling more nauseous than normal    YES  NO 
18. I am having more headaches than normal   YES  NO 
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Appendix E 
 
DATA COLLECTION FORM 
 
Name:      Participant ID: Visit Date:   
 
 
Visit Phase: Follicular Ovulation Luteal   
 
 
Height (cm):   Weight (kg):    
 
 
Standing Q-Angle:   Supine Q-Angle:   
 
 
Grip Hand R  L Grip Strength (highest):    
 
 
Rested Joint Laxity: Measure 1:  Measure 2:  Measure 3:   
 
 
Fatigued Joint Laxity: Measure 1:  Measure 2:  Measure 3:   
 
 
Peak Torque 180:   50% Peak Torque:   Reps to 
Fatigue:    
 
 
DXA Completed: YES NO Not Applicable  
 
 
Lean Mass:   Fat Mass:   Percent Fat:   
   
 
 
Blood Draw Success:  YES NO 
 
 
Biodex Completed: YES NO  
 
 
Notes:            
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Appendix F 
 
Using Ovulation Test Kits 
 
1. Try to take the test the first time you urinate in the morning.  If you forget, DO NOT 
skip the test, but rather take it when you remember. 
2. Pass a small amount of urine into the cup provided. 
3. While holding the test strip by the blue portion, immerse the strip in urine close to but 
not past the MAX line for three seconds. 
4. Remove the strip from the urine and lay the strip flat for 5 minutes. 
5. If a line that matches the control line appears, the test is positive.  Call or email Lee to 
schedule an appointment 
 
If you have any questions regarding this part of the study, call Lee at 507-829-1631. 
 
Thank you 
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Appendix G 
 
Consent to Participate in a Research Project 
South Dakota State University 
Brookings, SD 57007 
 
Department of: Ethel Austin Martin Program in Human Nutrition 
Project Director: Lee Weidauer, PhD    Phone Number: (605) 688-4630  
E-mail: Lee.Weidauer@sdstate.edu   Date _____________________ 
Please read (listen to) the following information: 
1. This is an invitation for you to participate in a research project under the direction of 
Dr. Lee Weidauer. 
2. The project is entitled The Role of the Menstrual Cycle in Neuromuscular Risk Factors 
for ACL Injuries. 
3. The purpose of the project is to determine the change in neuromuscular performance 
throughout the menstrual cycle in college-aged females and the effect of hormonal 
contraception on these changes. 
4. If you consent to participate, you will be involved in the following process which will 
take about 3 hours of your time: 
Questionnaires 
 You will be asked to complete a medical history questionnaire.  This questionnaire 
will ask you to list any medications you are taking and also ask you about certain medical 
conditions you may or may not have.  Additionally, you will be asked to complete a 
questionnaire that will ask you about certain symptoms related to your menstrual cycle 
that you may or may not be experiencing. 
 
Height and Weight 
 We will measure your height and weight without shoes and wearing light clothing.  
 
Grip Strength 
 We will measure your grip strength using a device that you will be asked to squeeze 
as hard as you can for 3 seconds.    
 
Quadriceps Angle 
 Quadriceps angle will be measured to the nearest degree using a goniometer.  
Quadriceps angle is the angle formed by a line connecting the anterior, superior, iliac 
spine to the patellar midline and then patellar midline to the midline of the tibial tubercle.   
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Body Composition 
Dual-Energy X-Ray absorptiometry (DXA) scans will be completed on the EA 
Martin Program’s mobile unit.  The scan takes approximately 3 minutes to complete and 
provides a measure of body composition.   
 
24 Hour Diet Record 
You will be asked to complete a 24 hour diet log.  Diet logs will be completed online 
using ASA24 software.  The software uses a system that allows you several different 
chances to log everything you ate on a given day to ensure high quality dietary data is 
collected.  
  
Blood Tests 
 A small needle will be used to draw 10ml of blood from a vein in your arm by a 
trained phlebotomist.  The blood will be analyzed for estradiol, progesterone, and relaxin 
using radioimmunoassay.  
 
Leg Strength 
 You will be asked to complete a series of leg exercises.  You will be asked to push 
as hard as you can against the machine while the speed of your movement is limited to 
60, 180, and 280 degrees per second. 
 
Joint Laxity 
 We will measure the amount of movement in your knee using a KT 1000.  The KT 
1000 is a non-invasive and safe method to measure movement in the knee.  During this 
test you will be asked to lie flat on your back while relaxing the muscles in your leg 
 
5. Participation in this project is voluntary. You have the right to withdraw at any time 
without penalty and doing so will not affect you in any way.   If you have any 
questions, you may contact the project director at the number listed above. 
6. You may experience lower extremity muscle fatigue and soreness from the isokinetic 
testing.  You may experience discomfort and possible bruising at the site of your blood 
draw.  You may feel uncomfortable providing some information to us and can decide 
if there is a question you do not want to answer.  You will be exposed to a small 
amount of radiation during the whole body DXA scan.  A total body DXA has a 
radiation dose of 0.35mrem.  This is lower than the radiation dose of a transcontinental 
flight (5mrem). 
7. There are no direct benefits to you as a result of participation in this study; however, 
you will be given data regarding body composition and leg strength that might help 
you in making positive lifestyle decisions.  
61 
 
8. As a thank you for your participation, you will be given 60 dollars as a thank you for 
your participation. 
9. Your responses are strictly confidential. When the data and analysis are presented, you 
will not be linked to the data by your name, title or any other identifying item. 
 
As a research participant, I have read the above, have had any questions answered, and 
agree to participate in the research project and acknowledge that I have received a 
copy of this form for my information. 
 
Participant's Signature ______________________________ Date __________   
 
Project Director's Signature __________________________ Date __________   
If you have any questions regarding this study you may contact the Project Director. If 
you have questions regarding your rights as a participant, you can contact the SDSU 
Research Compliance Coordinator at (605) 688-6975 or SDSU.IRB@sdstate.edu. 
 
This project has been approved by the SDSU Institutional Review Board, Approval  
No.: ______   
 
Human Subjects Committee - Checklist  
South Dakota State University 
COMPLETE by checking all appropriate items and INCLUDE THIS SHEET IN ALL SUBMISSIONS 
 
Project Director:  Lee Weidauer           
 
Project Title:  The role of the menstrual cycle in neuromuscular risk factors for ACL injuries    
 
TITLE 
1. _X_ Does the title of the study appear and match the title used throughout the proposal? 
INVITATION TO PARTICIPATE 
2. _X_ Does the consent form begin with a clear invitation to participate? 
3. _X_ Is there a description of who participants will be; how they were selected? 
PURPOSE 
4. _X_ Is there a clear statement of the purpose of the research? 
5. _X_ Does it state who is conducting the research? 
6. _X_ Does the consent form state that participation is voluntary? 
7. _X_ Is it stated that the participant may withdraw without penalty? 
PROCEDURES 
8. _X_ Is the explanation of procedures adequate?  
9. _X_ Are copies of the instruments attached? 
10. _X_ Has permission to use instruments been obtained, if was developed by someone else? 
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11. _X_ Does it state amount of time the participant will be involved? 
BENEFITS 
12_X_ Is the statement of potential benefits complete? 
COMPENSATION 
13. _X_ Is the availability of compensation stated? 
14. __ Is there any cost to the participants? 
15. __ Is there compensation in case of injury? 
16. __ Is there alternative treatment available? 
17. __ Is there a statement on emergency medical treatment (for more than minimal risk studies)? 
RISKS 
18. _X_ Is the description of the potential risks and discomforts complete? 
19. _X_ Are methods of risk reduction in place? (i.e., referral in case of upset due to questions asked) 
20. _X_ Does it state that the investigator may remove a participant from the study if it is in their best interest? 
CONFIDENTIALITY 
21. __ Is the assurance of confidentiality, when applicable clear and complete? 
22. __ Is the FDA access (or other access) to research records statement included, if applicable? 
23. _X_ Has the participant had an opportunity to ask questions and they have been provided with contact information 
should they questions in the future? 
24. _X_ Does it state that participants will receive a copy of the consent form? 
SIGNATURES 
25. _X_ Are there dated subject and investigator blanks? 
GENERAL QUESTIONS 
26. _X_ Is the investigator's name and phone number on the form (i.e., signature block) 
27. _X_ Is the consent form written in "lay language"? 
 28. _X_ Is the consent form free of any exculpatory language? (That is, no PI can claim that they are not responsible for 
anything that happens to a participant do to their participation in their study). 
29. __ If children are included as subjects, is provision made for securing the assent of the child and the consent of the 
parent/guardian? 
30. __ Has permission been obtained from schools, agencies involved? 
31. _X_ What is the overall risk classification?  Minimal?  Greater than minimal? 
PROTOCOL QUESTIONS 
32. __ Do you have any major questions pertaining to the protocol (indicate on back with page # and section 
referenced)? 
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 Additional Research Staff: 
 
Name Title/Department Telephone/Email 
   
Bonny Specker, 
PhD 
Director and Endowed Chair 605-688-1644 
 EA Martin Program Bonny.Specker@sdstate.edu 
Matt Vukovich, 
PhD 
Department Head 605-688-6580 
 Health and Nutritional Sciences Matt.Vukovich@sdstate.edu 
Jeffrey Clapper, 
PhD 
Professor 605-688-5417 
 Animal Science Jeffrey.Clapper@sdstate.edu 
Mary Beth Zwart, 
EdD 
Assistant Professor 605-688-5325 
 Health and Nutritional Sciences MaryBeth.Zwart@sdstate.edu 
Joseph Albert, ATC Graduate Student 
Health and Nutritional Sciences 
712-540-4505 
Joseph.albert@sdstate.edu 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
